Crossmark

Documents that mention this clinical trial

SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
https://doi.org/10.1136/annrheumdis-2018-eular.3115

FRI0462 UNDERSTANDING MEDIATORS OF PAIN REDUCTION IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH TOFACITINIB: ROLE OF INFLAMMATION
https://doi.org/10.1136/annrheumdis-2019-eular.1921

Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies
https://doi.org/10.1186/s41927-022-00298-4

Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
https://doi.org/10.1007/s40744-021-00405-w

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis ^(Results)
https://doi.org/10.1136/rmdopen-2022-002478

POS1025 TOFACITINIB TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS AND PROBABLE DEPRESSION AND/OR ANXIETY: A POST HOC ANALYSIS OF TWO PHASE 3 CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.176

AB0902 Efficacy of tofacitinib by background methotrexate dose in patients with psoriatic arthritis: a post-hoc analysis of pooled data from 2 phase 3 trials
https://doi.org/10.1136/annrheumdis-2018-eular.1278

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
https://doi.org/10.1136/rmdopen-2021-001609

AB0774 TIME TO RESPONSE FOR CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH TOFACITINIB, ADALIMUMAB OR PLACEBO
https://doi.org/10.1136/annrheumdis-2020-eular.994

POS1544 LONG-TERM SAFETY AND EFFICACY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS BY PRIOR BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG EXPOSURE
https://doi.org/10.1136/annrheumdis-2023-eular.3308

Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis
https://doi.org/10.1007/s40744-022-00482-5

Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies
https://doi.org/10.1136/rmdopen-2024-005250

AB0768 BASELINE PAIN SEVERITY AS A PREDICTOR OF PAIN IMPROVEMENT FOLLOWING TREATMENT WITH TOFACITINIB IN PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2019-eular.1364

POS1020 EFFICACY OF TOFACITINIB ON DACTYLITIS IN INDIVIDUAL DIGITS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.73

SAT0469 Integrated efficacy analysis of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.2444

SAT0317 Tofacitinib in patients with psoriatic arthritis and metabolic syndrome: a post-hoc analysis of phase 3 studies
https://doi.org/10.1136/annrheumdis-2018-eular.3242

AB0827 IMPACT OF BASELINE BODY MASS INDEX ON THE EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2020-eular.993

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2019-001042

Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study
https://doi.org/10.1136/rmdopen-2022-002559

FRI0335 THE EFFECT OF TOFACITINIB ON RESIDUAL PAIN IN PATIENTS WITH PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2020-eular.949

FRI0496 Comparing tofacitinib safety profile in patients with psoriatic arthritis in clinical studies with real-world data
https://doi.org/10.1136/annrheumdis-2017-eular.2448

AB0831 COMPARISON OF DIFFERENT REMISSION INDICES IN PATIENTS WITH PSORIATIC ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM PHASE 3 TOFACITINIB STUDIES
https://doi.org/10.1136/annrheumdis-2020-eular.948

AB0838 IDENTIFYING MEDIATORS OF PAIN REDUCTION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH TOFACITINIB: ROLE OF INFLAMMATION ASSOCIATED WITH PERIPHERAL ARTHRITIS, ENTHESITIS AND SKIN DISEASE
https://doi.org/10.1136/annrheumdis-2020-eular.1052

Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis
https://doi.org/10.1136/rmdopen-2020-001486

OP0052 THE EFFECT OF TOFACITINIB ON RESIDUAL PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS WITH COMPLETE CONTROL OF INFLAMMATION
https://doi.org/10.1136/annrheumdis-2022-eular.58

AB0837 ITCH AS THE MAJOR MEDIATOR OF THE EFFECT OF TOFACITINIB ON HEALTH-RELATED QUALITY OF LIFE IN PsA: A MEDIATION ANALYSIS
https://doi.org/10.1136/annrheumdis-2020-eular.1808

POS1045 MASS SPECTROMETRY-BASED PROTEOMICS FOR THE IDENTIFICATION OF CANDIDATE SERUM PROTEIN BIOMARKERS THAT MAY PREDICT TREATMENT RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2022-eular.2091

THU0299 An integrated analysis of changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis across phase 3 and long-term extension studies
https://doi.org/10.1136/annrheumdis-2018-eular.1459

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
https://doi.org/10.1136/rmdopen-2018-000808

AB0794 Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis: results from two phase 3 studies
https://doi.org/10.1136/annrheumdis-2017-eular.2445

SAT0221 Effect of tofacitinib on reducing pain in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/annrheumdis-2018-eular.3247

AB0921 Impact of baseline demographics, disease activity and concomitant medication on american college of rheumatology 20 response rate and health assessment questionnaire-disability index score with tofacitinib in active psoriatic arthritis: a pooled subgroup analysis of 2 phase 3 studies
https://doi.org/10.1136/annrheumdis-2018-eular.3210

OP0225 TOFACITINIB AS MONOTHERAPY FOLLOWING METHOTREXATE WITHDRAWAL IN PATIENTS WITH PSORIATIC ARTHRITIS PREVIOUSLY TREATED WITH OPEN-LABEL TOFACITINIB + METHOTREXATE: A RANDOMISED, PLACEBO-CONTROLLED SUBSTUDY OF OPAL BALANCE
https://doi.org/10.1136/annrheumdis-2020-eular.529

SAT0330 Changes in lymphocytes and lymphocyte subsets in tofacitinib-treated patients with psoriatic arthritis
https://doi.org/10.1136/annrheumdis-2018-eular.3490

An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data
https://doi.org/10.1007/s40264-020-00904-9

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
https://doi.org/10.1136/rmdopen-2018-000806

SAT0439 Integrated safety summary of tofacitinib in psoriatic arthritis clinical studies
https://doi.org/10.1136/annrheumdis-2017-eular.1573

Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension
https://doi.org/10.1136/rmdopen-2022-002718

FRI0509 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 24 months in patients with active psoriatic arthritis: interim data from opal balance, an open-label, long-term extension study
https://doi.org/10.1136/annrheumdis-2017-eular.1414

Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064

THU0323 Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
https://doi.org/10.1136/annrheumdis-2018-eular.1275

Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z

Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52
https://doi.org/10.1136/annrheumdis-2020-217372

FRI0452 TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF DERMATOLOGIC ENDPOINTS FROM 2 PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2019-eular.798